Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials (SPECTRUM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05335876 |
Recruitment Status :
Recruiting
First Posted : April 20, 2022
Last Update Posted : April 4, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Spinal Muscular Atrophy (SMA) | Biological: onasemnogene abeparvovec | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 260 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials |
Actual Study Start Date : | December 19, 2022 |
Estimated Primary Completion Date : | October 18, 2039 |
Estimated Study Completion Date : | October 18, 2039 |
Arm | Intervention/treatment |
---|---|
Experimental: Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec
Patients who received OAV101 IT or OAV101 IV in clinical trials (COAV101A12306, COAV101B12301 and COAV101B12302)
|
Biological: onasemnogene abeparvovec
Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
Other Name: Zolgensma |
- Number of participants with treatment-emergent serious adverse events (SAEs) [ Time Frame: Up to Year 15 ]
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria:
- fatal
- life-threatening
- results in persistent or significant disability/incapacity
- constitutes a congenital anomaly/birth defect, fetal death or congenital abnormality or birth defect
- requires in-patient hospitalization or prolongation of existing hospitalization, unless hospitalization is for routine treatment or monitoring of the studied indication, not associated with any deterioration in condition
- is medically significant, e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above
- Number of participants with treatment emergent Adverse Events of Special Interest (AESI) [ Time Frame: Up to Year 15 ]The following are important identified and important potential risks (AESI) associated with OAV101: Hepatotoxicity, Transient Thrombocytopenia, Cardiac adverse events, Sensory abnormalities suggestive of ganglionopathy, and Thrombotic microangiopathy. These will be assessed by the investigator.
- The number of participants demonstrating each developmental milestone according to the Developmental Milestone Checklist [ Time Frame: Up to Year 5 ]The Developmental Milestone Checklist is a sponsor created list of items using relevant definitions obtained from World Health Organization Multicentre Growth Reference Study (WHO-MGRS). These will be assessed via the milestone checklist, formed of 6 yes/no questions. The developmental milestones are: sitting with support, hands-and-knees crawling, standing with assistance, walking with assistance, standing alone and walking alone. A yes response indicates that the patient reached a particular development milestone.
- The number of participants demonstrating maintenance of each developmental milestone according to the Developmental Milestone Checklist [ Time Frame: Up to Year 5 ]The Developmental Milestone Checklist is a sponsor created list of items using relevant definitions obtained from World Health Organization Multicentre Growth Reference Study (WHO-MGRS). These will be assessed via the milestone checklist, formed of 6 yes/no questions. The developmental milestones are: sitting with support, hands-and-knees crawling, standing with assistance, walking with assistance, standing alone and walking alone. A yes response indicates that the patient reached a particular development milestone.
- Change from Baseline in the Hammersmith Functional Motor Scale - Expanded (HFMSE) total score [ Time Frame: Up to Year 5 ]The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.
- Change from Baseline in the Revised Upper Limb Module (RULM) total score [ Time Frame: Up to Year 5 ]The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in ambulatory and non-ambulatory individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.
- Systolic and diastolic blood pressure (mmHg) [ Time Frame: Up to Year 15 ]
- Number of patients with potentialy clinically significant vital sign findings - Respiratory Rate (breaths/min) [ Time Frame: Up to Year 15 ]
- Number of patients with potentialy clinically significant vital sign findings -Pulse Rate (beats/min) [ Time Frame: Up to Year 15 ]
- Number of patients with potentialy clinically significant vital sign findings -Temperature (Degrees Celsius) [ Time Frame: Up to Year 15 ]
- Number of patients with potentialy clinically significant vital sign findings -Oxygen saturation level (%). [ Time Frame: Up to Year 15 ]Oxygen saturation is the fraction of oxygen-saturated hemoglobin relative to total hemoglobin (unsaturated+saturated) in the blood and then multiplied by 100.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participated in an OAV101 clinical trial.
- Written informed consent must be obtained before any assessment is performed.
- Patient/Parent/legal guardian willing and able to comply with study procedures.
Exclusion Criteria:
There are no exclusion criteria for this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05335876
Contact: Novartis Gene Therapies Med Info (US, Latin America, Canada) | +1-833-828-3947 | medinfo.gtx@novartis.com | |
Contact: Novartis Gene Therapies Med Info (Europe, Middle East, Africa, Asia-Pacific) | +353 (1) 566-2364 | medinfoemea.gtx@novartis.com |
United States, Virginia | |
Child Hosp of the Kings Daughters | Recruiting |
Norfolk, Virginia, United States, 23507 | |
Contact: Erin Smith 757-668-9026 erin.smith@chkd.org | |
Principal Investigator: Crystal Proud | |
Australia, New South Wales | |
Novartis Investigative Site | Recruiting |
Randwick, New South Wales, Australia, 2031 | |
Belgium | |
Novartis Investigative Site | Recruiting |
Leuven, Belgium, 3000 | |
Canada, Quebec | |
Novartis Investigative Site | Recruiting |
Montreal, Quebec, Canada, H4A 3J1 | |
Denmark | |
Novartis Investigative Site | Recruiting |
Copenhagen, Denmark, 2100 O | |
France | |
Novartis Investigative Site | Recruiting |
Garches, France, 92380 | |
Novartis Investigative Site | Recruiting |
Strasbourg, France, 67000 | |
Italy | |
Novartis Investigative Site | Recruiting |
Roma, RM, Italy, 00168 | |
Japan | |
Novartis Investigative Site | Recruiting |
Kurume city, Fukuoka, Japan, 830-0011 | |
Singapore | |
Novartis Investigative Site | Recruiting |
Singapore, Singapore, 119074 | |
Spain | |
Novartis Investigative Site | Recruiting |
Barcelona, Catalunya, Spain, 08035 | |
Taiwan | |
Novartis Investigative Site | Recruiting |
Kaohsiung, Taiwan, 80756 | |
Novartis Investigative Site | Recruiting |
Taipei, Taiwan, 10002 | |
United Kingdom | |
Novartis Investigative Site | Recruiting |
London, United Kingdom, WC1N 3JH | |
Novartis Investigative Site | Recruiting |
Newcastle Upon Tyne, United Kingdom, NE1 4LP |
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT05335876 |
Other Study ID Numbers: |
COAV101A12308 |
First Posted: | April 20, 2022 Key Record Dates |
Last Update Posted: | April 4, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/. |
URL: | https://www.clinicalstudydatarequest.com/ |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Zolgensma OAV101 AVXS 101 gene therapy Muscle atrophy SBMA spinal and bulbar muscular atrophy spinal muscular atrophy bulbar muscular atrophy muscle function myopathy |
muscle wasting atrophied muscle loss of muscle strength Spinal Muscular Atrophy (SMA) survival motor neuron 1 gene (SMN1) SMN protein depletion survival motor neuron 2 gene (SMN2) chromosome 5q13 neurogenetic disorder onasemnogene abeparvovec |
Muscular Atrophy Muscular Atrophy, Spinal Atrophy Pathological Conditions, Anatomical Neuromuscular Manifestations Neurologic Manifestations |
Nervous System Diseases Spinal Cord Diseases Central Nervous System Diseases Motor Neuron Disease Neurodegenerative Diseases Neuromuscular Diseases |